Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Creative Essences Inc
WARNING LETTER
•Creative Essences Inc•March 25, 2025

Creative Essences Inc – FDA Warning Letter, Mar 25, 2025

Record Details

The FDA issued a Warning Letter to Creative Essences, Inc. following an inspection of its Santa Fe Springs drug manufacturing facility from March 19 to 25, 2025. The letter details significant violations of Current Good Manufacturing Practice (CGMP) regulations, rendering the company"s drug products adulterated under the Federal Food, Drug, and Cosmetic Act.

Key issues included the firm"s failure to thoroughly investigate unexplained discrepancies and out-of-specification (OOS) results, such as an OOS active pharmaceutical ingredient, microbial OOS from the water system, and stability failures for a sunscreen product. The company"s quality unit did not adequately identify root causes, implement effective corrective actions, or assess the impact on other batches. Furthermore, Creative Essences, Inc. lacked adequate laboratory controls, including insufficient sampling and testing procedures for finished drug products, and failed to demonstrate the suitability of its microbiological test methods. The FDA also identified one drug product as an unapproved new drug and misbranded.

The FDA requires comprehensive, independent assessments and remediation plans for the company"s deviation investigation and corrective and preventive action (CAPA) programs. This includes improving investigation competencies, root cause analysis, and quality unit oversight. Additionally, the company must conduct an independent assessment of its laboratory practices, providing a detailed remediation plan, a list of all specifications, and a plan for full chemical and microbiological testing of retain samples for all distributed drug products currently within their expiry period.

Company
Creative Essences Inc
Inspection date
March 25, 2025
Product type
Other
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Tina Smith (Director)
  • Brad Pace (Associate Director)
View Company Profile

ID · 31117288-acdc-4260-a1ca-8e478e0a0da8

Violation Codes10
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)FD&C Act 505(a)FD&C Act 502(ee)21 U.S.C. 352(ee)FD&C Act 301(d)FD&C Act 301(a)21 CFR 211.84(d)(1)21 CFR 211.2221 CFR 211.84(d)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Creative Essences Inc
  • 483 - 2025-03-25March 25, 2025
  • 483 - 2020-09-04September 4, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Creative Essences Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.